Ireland - English - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - alpha-1-proteinase inhibitor - powder and solvent for solution for infusion - 1000 milligram(s) - proteinase inhibitors; alfa1 antitrypsin

Ireland - English - HPRA (Health Products Regulatory Authority)

nordic group b.v. - aprotinin concentrated solution - solution for injection/infusion - 10,000 kallikrein inactivator unit/millilitre - proteinase inhibitors; aprotinin

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

Canada - English - Health Canada

csl behring canada inc - alpha1-proteinase inhibitor (human) - kit - 1000mg - alpha1-proteinase inhibitor (human) 1000mg - enzymes

United States - English - NLM (National Library of Medicine)

apotheca company - artemisia abrotanum flowering top (unii: qg07g580u0) (artemisia abrotanum flowering top - unii:qg07g580u0), semecarpus anacardium juice (unii: y0f0bu8rdu) (semecarpus anacardium juice - unii:y0f0bu8rdu), arsenic trioxide (unii: s7v92p67ho) (arsenic trioxide - unii:s7v92p67ho), barium chloride dihydrate (unii: el5gj3u77e) (barium cation - unii:v645272hln), helleborus niger root (unii: 608dgj6815) (helleborus niger root - unii:608dgj6815), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignatii see - artemisia abrotanum flowering top 30 [hp_c] in 1 ml - indications: supports weight loss by regulating male and female hormone functions and also suppressing ravenous appetite. indications:   supports weight loss by regulating male and female hormone functions and also suppressing ravenous appetite.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nordic pharma ltd - aprotinin - solution for infusion - 10000kallikrein inactivator unit/1ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules, usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase produci

Canada - English - Health Canada

csl behring canada inc - alpha1-proteinase inhibitor (human) - kit - 4000mg - alpha1-proteinase inhibitor (human) 4000mg - enzymes

Canada - English - Health Canada

csl behring canada inc - alpha1-proteinase inhibitor (human) - kit - 5000mg - alpha1-proteinase inhibitor (human) 5000mg - enzymes